FDA Grants Breakthrough Device Designation to Guardant Health's Shield Multi-Cancer Detection (MCD) Test
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that its Shield multi-cancer detection (MCD) test has been granted Breakthrough Device designation from the U.S. Food and Drug Administration (FDA). The Shield MCD test is a methylation-based blood test for the multi-cancer screening of multiple cancer types including bladder, colorectal, esophageal, gastric, liver, lung, ovarian and pancreas cancer in individuals aged 45 or older who are at typical average risk for cancer.
The FDA grants Breakthrough Device designation to a limited set of qualifying devices that have the potential to provide for more effective treatment or diagnosis of life-threatening diseases, such as cancer, than current options. The goal of the FDA's Breakthrough Devices Program is to provide patients and healthcare providers with timely access to medical devices by speeding up their development, assessment and review.
'Every late-stage cancer we avert is a win for patients and for the entire healthcare system,' said AmirAli Talasaz, Guardant Health co-founder and co-CEO. 'This recognition by the FDA shows the promise of the Shield MCD test to detect multiple cancers at an early stage with just a single, routine blood draw. We look forward to partnering with the agency and other stakeholders to bring this breakthrough to patients quickly.'
The Breakthrough Device designation by the FDA of the Shield MCD test builds on its recent selection by the National Cancer Institute (NCI) for the Vanguard Study evaluating emerging MCD technology. The Shield MCD test was chosen for the Vanguard study based on its strong performance in predicting the presence of cancers and cancer tissue of origin.
At the 2025 American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago, Guardant presented data on the clinical validation of the Shield MCD test showing that the blood-based test exhibits high specificity, clinically meaningful sensitivity and strong cancer signal of origin accuracy across multiple tumor types. The data presented from a case-control cohort showed that the Shield MCD test has 98.6% specificity and 75% cancer sensitivity across bladder, colorectal, esophageal, gastric, liver, lung, ovarian and pancreas cancers (per-cancer sensitivity range: 62-96%). Primary or secondary CSO (cancer signal origin) accuracy was 92%.
About Guardant Health
Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health's liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health's financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operation' and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2024, and in its other reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health's views as of any date subsequent to the date of this press release.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
25 minutes ago
- Business Insider
Top Analyst Amit Daryanani Sets Expectations on Apple Stock Ahead of WWDC 2025
Apple (NASDAQ:AAPL) has frequently ranked among the world's two most valuable companies, but it has now slipped to third place as the tech giant faces pressure from multiple fronts, all of which are dampening investor sentiment. Confident Investing Starts Here: The stock has shed 19% this year, dragged down by concerns over antitrust investigations, tariffs, competition in China, and its positioning in AI. The decline makes Apple the weakest performer among the Mag 7 tech giants and puts it well behind the S&P 500, which has gained 1.5% in 2025. So, with WWDC 2025 (June 9–13) on the horizon, will Apple make a push to close the gap with its big tech peers? Not quite, says Evercore's Amit Daryanani, an analyst ranked in the top 4% of Wall Street stock experts. Daryanani thinks that compared to previous years, which featured bigger announcements like Apple Intelligence in 2024 and Vision Pro in 2023, expectations are 'rightfully tempered.' Daryanani reckons the biggest announcement will likely be Apple making its foundation models available to app developers, enabling them to use on-device AI. Additionally, Apple might reveal new partner options beyond OpenAI for its Apple Intelligence platform, which will be built directly into iOS – with Perplexity and Gemini seen as likely candidates. The company is also planning a more extensive update to its operating systems than usual, along with a new naming convention that adds the year at the end, such as iOS 26. Another key announcement is expected to be a centralized gaming app that will come preinstalled on devices – a strategic move, given that gaming makes up around half of App Store revenue. While there could be a few smaller AI-related updates as well, they likely won't be significant enough to shift the prevailing view that Apple is still trailing behind in the AI space. But that take is not quite on the money, says Daryanani. 'We continue to think this narrative underestimates Apple's strategy, which is to focus on smaller scale on-device models and efficient large scale models while sitting out on the AI capex arms race,' the 5-star analyst opined. Rather than trying to match its peers by pouring tens or even hundreds of billions into AI infrastructure, Apple is sticking with a 'more capital light model.' The plan is to let other model providers do the heavy lifting, then charge them – either through revenue sharing or subscription fees – for access to Apple's iOS user base. Daryanani thinks this strategy gives Apple a way to potentially earn strong returns from AI while avoiding the financial risk of investing billions without a 'clear path to monetization.' 'Net/net,' Daryanani summed up, 'We think WWDC will be more low key this year with no hardware announcements or major overhauls on par with last year's Apple Intelligence. Instead we will see some incremental improvements with more meaningful updates expected in 2026.' All told, Daryanani assigns an Outperform (i.e., Buy) rating to Apple shares, along with a $250 price target that implies a one-year upside of 23%. (To watch Daryanani's track record, click here) 16 other analysts join Daryanani in the AAPL bull camp and with an additional 9 Holds and 4 Sells, the stock claims a Moderate Buy consensus rating. The average price target stands at $228.79, a figure that factors in 12-month returns of ~13%. (See AAPL stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.
Yahoo
26 minutes ago
- Yahoo
Alvotech and Dr. Reddy's Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)
HYDERABAD, India and REYKJAVIK, Iceland, June 05, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide ('Alvotech'), and Dr. Reddy's Laboratories Ltd., (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as 'Dr. Reddy's'), today announced that the companies have entered into a collaboration and license agreement to co-develop, manufacture and commercialize a biosimilar candidate to Keytruda® (pembrolizumab) for global markets. Keytruda® (pembrolizumab) is indicated for the treatment of numerous cancer types. In 2024, worldwide sales of Keytruda were US$29.5 billion [1]. The collaboration combines Dr. Reddy's and Alvotech's proven capabilities in biosimilars, thereby, speeding up the development process and extending the global reach for this biosimilar candidate. Under the terms of the agreement, the parties will be jointly responsible for developing and manufacturing the biosimilar candidate and sharing costs and responsibilities. Subject to certain exceptions, each party will have the right to commercialize the product globally. 'We are very pleased to enter into this collaboration for pembrolizumab with Dr. Reddy's. This agreement demonstrates Alvotech's ability to leverage its dedicated R&D and manufacturing platform for biosimilars, accelerating the expansion of our pipeline by pursuing growing global markets. It further enables us to increase the availability of cost-effective, critical biologic medications to patients world-wide,' said Róbert Wessman, chairman and CEO of Alvotech. 'We are happy to collaborate with Alvotech for the pembrolizumab biosimilar. This demonstrates our ability to develop and manufacture high quality and affordable treatment options for patients worldwide. Additionally, oncology has been a top focus therapy area for us and this collaboration will further enhance our capabilities in oncology, as pembrolizumab currently represents one of the most critical therapies in immuno-oncology,' said Erez Israeli, CEO of Dr. Reddy's. Use of trademarksKeytruda® is a registered trademark of Merck Sharp & Dohme Corp. Sources[1] Accessed on June 4, 2025. About AlvotechAlvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Two biosimilars, to Humira® (adalimumab) and Stelara® (ustekinumab) are already approved and marketed in multiple global markets. The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech's commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Dr. Reddy's (EEA, UK and US), Biogaran (FR), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit None of the information on the Alvotech website shall be deemed part of this press release. For more information visit Alvotech's investor portal, and website or follow Alvotech on social media on LinkedIn, Facebook, Instagram, and YouTube. Alvotech Forward Looking StatementsCertain statements in this communication may be considered 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements generally relate to future events or the future financial operating performance of Alvotech and may include, for example, Alvotech's expectations regarding competitive advantages, business prospects and opportunities including pipeline product development, future plans and intentions, results, level of activities, performance, goals or achievements or other future events, regulatory submissions, review and interactions, the potential approval and commercial launch of its product candidates, the timing of regulatory approval, and market launches. In some cases, you can identify forward-looking statements by terminology such as 'may', 'should', 'expect', 'intend', 'will', 'estimate', 'anticipate', 'believe', 'predict', 'potential', 'aim' or 'continue', or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Alvotech and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Alvotech's control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (1) the ability to develop or co-develop future products, including the proposed biosimilar to Keytruda®; (2) the ability to maintain stock exchange listing standards; (3) changes in applicable laws or regulations; (4) the possibility that Alvotech may be adversely affected by other economic, business, and/or competitive factors; (5) Alvotech's estimates of expenses and profitability; (6) Alvotech's ability to develop, manufacture and commercialize the products and product candidates in its pipeline; (7) actions of regulatory authorities, which may affect the initiation, timing and progress of clinical studies or future regulatory approvals or marketing authorizations; (8) the ability of Alvotech or its partners to respond to inspection findings and resolve deficiencies to the satisfaction of the regulators; (9) the ability of Alvotech or its partners to enroll and retain patients in clinical studies; (10) the ability of Alvotech or its partners to gain approval from regulators for planned clinical studies, study plans or sites; (11) the ability of Alvotech's partners to conduct, supervise and monitor existing and potential future clinical studies, which may impact development timelines and plans; (12) Alvotech's ability to obtain and maintain regulatory approval or authorizations of its products, including the timing or likelihood of expansion into additional markets or geographies; (13) the success of Alvotech's current and future collaborations, joint ventures, partnerships or licensing arrangements; (14) Alvotech's ability, and that of its commercial partners, to execute their commercialization strategy for approved products; (15) Alvotech's ability to manufacture sufficient commercial supply of its approved products; (16) the outcome of ongoing and future litigation regarding Alvotech's products and product candidates; (17) the impact of worsening macroeconomic conditions, including rising inflation and interest rates and general market conditions, conflicts in Ukraine, the Middle East and other global geopolitical tension, on the Company's business, financial position, strategy and anticipated milestones; and (18) other risks and uncertainties set forth in the sections entitled 'Risk Factors' and 'Cautionary Note Regarding Forward-Looking Statements' in documents that Alvotech may from time to time file or furnish with the SEC. There may be additional risks that Alvotech does not presently know or that Alvotech currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Alvotech does not undertake any duty to update these forward-looking statements or to inform the recipient of any matters of which any of them becomes aware of which may affect any matter referred to in this communication. Alvotech disclaims any and all liability for any loss or damage (whether foreseeable or not) suffered or incurred by any person or entity as a result of anything contained or omitted from this communication and such liability is expressly disclaimed. The recipient agrees that it shall not seek to sue or otherwise hold Alvotech or any of its directors, officers, employees, affiliates, agents, advisors, or representatives liable in any respect for the provision of this communication, the information contained in this communication, or the omission of any information from this communication. About Dr. Reddy's Laboratories Ltd:Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of 'Good Health Can't Wait', we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Our major markets include – USA, India, Russia & CIS countries, China, Brazil, and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan and invest in businesses of the future. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. Over the last 25 years, our Biologics team has developed into a fully integrated organization with robust capabilities in the development, manufacture and commercialization of a range of biosimilar products in oncology and immunology. We have a current portfolio of six commercial products marketed in India, with some products marketed in more than 30 other countries. In addition, we have several products in the pipeline in oncology and auto-immune diseases in various stages of development for global launches across developed as well as emerging markets. We are also ramping up manufacturing capacity to support our global expansion plans. In 2024, we launched our first biosimilar in the United Kingdom, Versavo® (biosimilar bevacizumab). This follows our launch of pegfilgrastim in the U.S and Europe through our partner. Our biosimilars business has a key role to play in driving both near-term and long-term growth. For more information, log on to: Dr. Reddy's DisclaimerThis press release may include statements of future expectations and other forward-looking statements that are based on the management's current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words 'may', 'will', 'should', 'expects', 'plans', 'intends', 'anticipates', 'believes', 'estimates', 'predicts', 'potential', or 'continue' and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to, without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers', products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the 'Risk Factors' and 'Forward-Looking Statements' sections of our Annual Report on Form 20-F for the year ended March 31, 2024. The company assumes no obligation to update any information contained herein. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Neither can there be any guarantee that, if approved, such generic or biosimilar products will be approved for all indications included in the reference product's label. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; the particular prescribing preferences of physicians and patients; competition in general, including potential approval of additional generic or biosimilar versions of such products. ALVOTECH CONTACTSBenedikt StefanssonVP Investor Relations and Global DR. REDDY'S CONTACTS Priya K Richa Periwal Corporate Communications Head of Investor Relations priyak@ richaperiwal@ in to access your portfolio
Yahoo
26 minutes ago
- Yahoo
The Descartes Systems Group Inc (DSGX) Q1 2026 Earnings Call Highlights: Strong Revenue Growth ...
Total Revenue: $168.7 million, up 11.5% from $151.3 million in Q1 last year. Services Revenue: $156.6 million, representing 93% of total revenue, up 13.6% year-over-year. Adjusted EBITDA: $75.1 million, 44.5% of revenue, up 12.1% from $67.0 million in Q1 last year. Net Income: $36.2 million, up 4% from $34.7 million in Q1 last year. Cash Flow from Operations: $53.6 million, 71% of adjusted EBITDA, down from $63.7 million in Q1 last year. Cash Balance: $176 million at the end of April, down from $236 million at the end of January. Gross Margin: 76.4% of revenue, slightly down from 76.6% in Q1 last year. Operating Expenses: Increased by 10.4% year-over-year, primarily due to acquisitions. Acquisition Cost: $115 million plus restructuring costs for 3GTMS. Restructuring Charge: $4 million in Q2, with expected annual cost savings of $15 million. Debt Status: Debt-free with an undrawn $350 million line of credit. Tax Rate: 24.4% of pretax income, expected to trend between 24% and 28% for the year. Warning! GuruFocus has detected 3 Warning Sign with VRNT. Release Date: June 04, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. The Descartes Systems Group Inc (NASDAQ:DSGX) reported a 12% increase in total revenues from the previous year, with services revenues up 14%. The company achieved a 9% increase in income from operations and a 12% rise in adjusted EBITDA, with an adjusted EBITDA margin improvement to 45%. The acquisition of 3GTMS, despite requiring restructuring, is expected to enhance the transportation management portfolio and provide additional functionality to existing customers. The MacroPoint real-time visibility business experienced strong demand, contributing to growth despite a challenging domestic truck market in the US. The Global Trade Intelligence business saw significant growth due to increased demand for tariff and duty information amid changing trade environments. The broader macro environment remains challenging, with shipment volumes down in various transportation modes, particularly in US-China trade. The company had to undertake a restructuring, impacting about 7% of its workforce, to prepare for potential future economic challenges. Cash flow from operations decreased to $53.6 million, down from $63.7 million in the same quarter last year, partly due to acquisition-related charges. The US's removal of the de minimis tariff exemption for Chinese imports led to temporary disruptions in the company's small package import business. Uncertainty in global trade and economic conditions is causing decision-making paralysis among customers, impacting transaction volumes and growth. Q: Can you provide more details on the workforce reduction and its impact on the business? A: Edward Ryan, CEO: The reduction was across the board, affecting various functional areas and geographies, totaling just under 200 people. This decision was made to maintain healthy margins and prepare for market uncertainties. AI advancements have facilitated some of these cuts. Q: What were the headwinds affecting organic services growth this quarter? A: Edward Ryan, CEO: Uncertainty in the market led to fluctuations in transaction volumes, particularly in customs and security filings. Ocean and truck volumes were down, influenced by tariff uncertainties, causing customers to hesitate in decision-making. Q: Have you observed any changes in renewal rates or sales pipeline conversion? A: Edward Ryan, CEO: There hasn't been a significant change in renewal rates or sales pipeline conversion. Sales momentum remains strong, and there have been no major customer defections or contract renegotiations. The future depends on economic developments and tariff negotiations. Q: How does the current downturn compare to previous ones like 2022 or 2023? A: Edward Ryan, CEO: The current situation feels less severe but is marked by greater uncertainty. Unlike past downturns, it's unclear if we're in a recession. The uncertainty stems from unresolved tariff negotiations and geopolitical tensions. Q: What is the status of the 3GTMS acquisition and its integration? A: Allan Brett, CFO: The 3GTMS acquisition is reflected in the baseline calibration. The integration process is ongoing, with efforts to align cost structures and leverage cross-selling opportunities. The acquisition is expected to enhance Descartes' transportation management offerings. Q: How is the competitive environment evolving, especially with recent industry consolidations? A: Edward Ryan, CEO: The competitive landscape is shifting, with prices coming down and private equity firms less active. Descartes is well-positioned to capitalize on acquisition opportunities due to its strong cash reserves and debt capacity. Q: Can you elaborate on the impact of the de minimis rule change on your business? A: Edward Ryan, CEO: The removal of the de minimis exemption for China led to a temporary pause in shipments, but Descartes benefited by offering alternative filing solutions. The company gained business from competitors unable to handle the new transaction types. Q: What are the growth prospects for the Global Trade Intelligence (GTI) solutions? A: Edward Ryan, CEO: GTI solutions, particularly tariffs and duties, are experiencing strong growth, approaching 20% year-over-year. The demand for accurate tariff information is driving this growth, alongside increased interest in data mining tools. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
